- Home
- NPV vs ACRS Comparison
NPV vs ACRS Comparison
Compare NPV & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPV
- ACRS
- Stock Information
- Founded
- NPV 1993
- ACRS 2012
- Country
- NPV United States
- ACRS United States
- Employees
- NPV N/A
- ACRS N/A
- Industry
- NPV Investment Managers
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- NPV Finance
- ACRS Health Care
- Exchange
- NPV Nasdaq
- ACRS Nasdaq
- Market Cap
- NPV 211.4M
- ACRS 198.2M
- IPO Year
- NPV N/A
- ACRS 2015
- Fundamental
- Price
- NPV $11.42
- ACRS $2.52
- Analyst Decision
- NPV
- ACRS Strong Buy
- Analyst Count
- NPV 0
- ACRS 9
- Target Price
- NPV N/A
- ACRS $9.25
- AVG Volume (30 Days)
- NPV 38.9K
- ACRS 1.3M
- Earning Date
- NPV 01-01-0001
- ACRS 11-06-2025
- Dividend Yield
- NPV 3.90%
- ACRS N/A
- EPS Growth
- NPV N/A
- ACRS N/A
- EPS
- NPV N/A
- ACRS N/A
- Revenue
- NPV N/A
- ACRS $16,789,000.00
- Revenue This Year
- NPV N/A
- ACRS N/A
- Revenue Next Year
- NPV N/A
- ACRS N/A
- P/E Ratio
- NPV N/A
- ACRS N/A
- Revenue Growth
- NPV N/A
- ACRS N/A
- 52 Week Low
- NPV $8.92
- ACRS $1.05
- 52 Week High
- NPV $11.55
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- NPV 47.18
- ACRS 67.33
- Support Level
- NPV $11.42
- ACRS $2.24
- Resistance Level
- NPV $11.57
- ACRS $2.47
- Average True Range (ATR)
- NPV 0.09
- ACRS 0.21
- MACD
- NPV -0.01
- ACRS 0.04
- Stochastic Oscillator
- NPV 37.66
- ACRS 88.64
About NPV Nuveen Virginia Quality Municipal Income Fund
Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities. Company mostly invest in Education and Civic Organizations, Tax Obligation/General, Healthcare, Utilities , Housing/Multifamily, Transportation, and Others.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.